ACCURAY INCORPORATED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.195 USD | +0.23% |
|
+1.15% | -22.44% |
| Sales 2024 * | 462M 38.54B | Sales 2025 * | 489M 40.82B | Capitalization | 217M 18.11B |
|---|---|---|---|---|---|
| Net income 2024 * | -8M -667M | Net income 2025 * | 13M 1.08B | EV / Sales 2024 * | 0.47 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.44 x |
| P/E ratio 2024 * |
-26.5
x | P/E ratio 2025 * |
16.4
x | Employees | 1,024 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on Accuray Incorporated
More recommendations
More press releases
| 1 day | +0.23% | ||
| 1 week | +1.15% | ||
| Current month | -11.13% | ||
| 1 month | -8.92% | ||
| 3 months | -23.25% | ||
| 6 months | -16.54% | ||
| Current year | -22.44% |
1 week
2.14
2.25
1 month
2.102.52
Current year
2.102.99
1 year
2.104.30
3 years
1.705.93
5 years
1.336.02
10 years
1.3310.01
| Managers | Title | Age | Since |
|---|---|---|---|
Suzanne Winter
CEO | Chief Executive Officer | 61 | 21/19/21 |
Ali Pervaiz
DFI | Director of Finance/CFO | 44 | 01/20/01 |
Frank Valentino
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Beverly A. Huss
BRD | Director/Board Member | 64 | 07/18/07 |
Robert Kill
BRD | Director/Board Member | 60 | 30/23/30 |
Suzanne Winter
CEO | Chief Executive Officer | 61 | 21/19/21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.67% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 2.195 | +0.23% | 106 973 |
| 26/24/26 | 2.19 | +0.46% | 344,340 |
| 25/24/25 | 2.18 | -0.91% | 359,341 |
| 24/24/24 | 2.2 | -0.90% | 293,900 |
| 23/24/23 | 2.22 | +2.30% | 414,401 |
Delayed Quote Nasdaq, April 29, 2024 at 09:41 pm IST
More quotes
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells, and supports solutions that are designed to deliver radiation treatments. Its solutions are designed to advance patient care during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, the Company also provides services, which include post-contract customer support (warranty period services and post warranty services), installation services, training, and other professional services.
Calendar
01/05/2024
- Q3 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.19
USD
Average target price
8.75
USD
Spread / Average Target
+299.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.44% | 217M | |
| +9.10% | 219B | |
| +7.55% | 183B | |
| +11.29% | 133B | |
| +25.34% | 108B | |
| +0.27% | 63.06B | |
| +12.89% | 52.02B | |
| -0.62% | 48.2B | |
| +0.37% | 40.37B | |
| +13.27% | 39.35B |
- Stock Market
- Equities
- ARAY Stock
